Browsing Tag
AVA6103
24 posts
Avacta Therapeutics (AIM: AVCT) secures FDA clearance for AVA6103 as pre|CISION platform enters its second clinical test
Avacta Therapeutics secures FDA IND clearance for AVA6103, advancing its pre|CISION platform into a second clinical program. Read what changes next.
Can Avacta (AIM: AVCT) sustain momentum as AVA6103 data signals tumor-targeting breakthrough?
Avacta shares trade flat after releasing new AVA6103 data. Can the tumor-targeting strategy sustain momentum into Phase 1? Find out what traders expect.
Can Avacta’s £16m fundraise extend its oncology momentum after 91% disease control rate?
Avacta raises £16m to extend clinical runway into 2026 and reports 91% disease control in cancer trial. See why investors are watching AVCT closely.
Will Avacta’s pre|CISION platform turn its £3.25m bond repayment into a precision oncology breakthrough?
Avacta Group plc raises £3.25M to repay its convertible bond and extend clinical runway for its pre|CISION cancer drugs—find out what’s next.